AB 2199: Healing arts: clinical laboratories.
- Session Year: 2019-2020
- House: Assembly
- Latest Version Date: 2020-09-24
|
Date
|
Status
|
|---|---|
| Sep 24, 2020 | Chaptered by Secretary of State - Chapter 127, Statutes of 2020. |
| Sep 24, 2020 | Approved by the Governor. |
| Sep 15, 2020 | Enrolled and presented to the Governor at 3 p.m. |
| Aug 31, 2020 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 73. Noes 0. Page 5426.). |
| Aug 30, 2020 | In Assembly. Concurrence in Senate amendments pending. |
| Aug 30, 2020 | Read third time. Passed. Ordered to the Assembly. (Ayes 39. Noes 0.). |
| Aug 26, 2020 | Read second time. Ordered to third reading. |
| Aug 25, 2020 | Read third time and amended. Ordered to second reading. |
| Aug 18, 2020 | Read second time. Ordered to third reading. |
| Aug 17, 2020 | From committee: Be ordered to second reading pursuant to Senate Rule 28.8. |
| Aug 10, 2020 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 9. Noes 0.) (August 8). Re-referred to Com. on APPR. |
| Jun 23, 2020 | Referred to Com. on B., P. & E.D. |
| Jun 9, 2020 | In Senate. Read first time. To Com. on RLS. for assignment. |
| Jun 8, 2020 | Read third time. Passed. Ordered to the Senate. (Ayes 72. Noes 0. Page 4687.) |
| Jun 3, 2020 | Read second time. Ordered to third reading. |
| Jun 2, 2020 | From committee: Do pass. (Ayes 18. Noes 0.) (June 2). |
| May 22, 2020 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 18. Noes 0.) (May 21). Re-referred to Com. on APPR. |
| May 19, 2020 | Re-referred to Com. on B. & P. |
| May 18, 2020 | From committee chair, with author's amendments: Amend, and re-refer to Com. on B. & P. Read second time and amended. |
| Mar 5, 2020 | Referred to Com. on B. & P. |
| Feb 13, 2020 | From printer. May be heard in committee March 14. |
| Feb 12, 2020 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 31, 2020 | AB 2199 Nazarian Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Aug 30, 2020 | Assembly 3rd Reading AB2199 Nazarian By Glazer | Senate Floor |
Passed |
|
| Aug 8, 2020 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Business, Professions and Economic Development |
Passed |
|
| Jun 8, 2020 | AB 2199 Nazarian Assembly Third Reading | Assembly Floor |
Passed |
|
| Jun 2, 2020 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| May 21, 2020 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Business and Professions |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 2199
Author:(Nazarian)
As Amended Ver:August 25, 2020
Majority vote
SUMMARY:
Extends the authorization for laboratory personnel who meet specified requirements to perform a total protein test using a digital refractometer in a licensed plasma collection center in this state until January 1, 2023, and adds a clinical laboratory scientist as one of the personnel who can supervise the person.
The Senate Amendments:
Deleted the reference to a plasma collection center's parent company in reference to the required standardized procedures and made a technical change.
COMMENTS:
Background. This bill would extend an exemption under California clinical laboratory testing requirements by two years, allowing an unlicensed individual to perform a total protein test using a digital refractometer during the donor screening process at plasma donation centers until January 1, 2023. The sponsor of this bill represents private sector manufacturers of plasma protein therapies and collectors of source plasma. According to the sponsor, plasma protein therapies are used to treat medical conditions resulting from insufficient levels of plasma protein, including immune deficiencies and bleeding disorders.
Plasma Donation and COVID-19. The sponsors of this bill report that they are developing potential treatments for COVID-19 patients using plasma donated by individuals who have recovered from COVID-19. The goal is to use the antibodies found in the collected manufacture of hyperimmune globulins to treat COVID-19 patients. The convalescent plasma is being collected at licensed plasma donation centers in the United States, including California.
According to the Author:
"By allowing trained and qualified plasma donation centers employees to perform the total protein test with a digital refractometer, [this bill] will make sure four things: 1) licensed individuals are utilized to the highest level of their job skills resulting in more efficient source plasma donor screening; 2) it will ensure appropriate controls are in place for the digital refractometer to maintain continued donor safety when a Total Protein Test is administered; 3) bring California in line with the majority of other states that allow a Total Protein Test to be administered this way and; 4) will ensure Californians with rare disease have appropriate access to the 'lifesaving drug' that plasma proteins therapies provide."
Arguments in Support:
The Plasma Protein Therapeutics Association writes in support, "In 2018, The California Legislature passed legislation to create a pilot to determine if a properly trained individual may satisfactorily perform a total protein test using a digital refractometer in a licensed plasma collection center. This is the federal standard followed in most of the 44 states where plasma is donated.
The pilot has shown that the properly trained, but unlicensed individual is able to satisfactorily perform the total protein test with no harm to the potential donor. These results are not surprising since properly trained but unlicensed individuals perform the total protein test using a digital refractometer in more than 800 source plasma donation centers in the United States. The test is done to make sure an individual is suitable to donate source plasma on a given day.
[This bill] will ensure that licensed professionals are utilized to the highest level of their job skills resulting in more efficient source plasma donor screening. It will free up specialized staff to perform other essential functions in these source plasma donation centers, such as conducting new donor physical examinations. This is critical because the growing clinical need for plasma medicines means we need more source plasma donations. It takes more than 130 source plasma donations to manufacture the Ig needed annually to treat an individual with primary immune deficiency….
This is where California may make a difference. California currently has 26 source plasma donation centers. This is a result of laws that are not conducive to source plasma donation. For comparison, there are more than 100 source plasma donation centers in Texas, more than 60 in Florida, and more than 40 in Ohio…. Plasma donation centers benefit the communities they are in by providing good jobs to more than 50 employees per center and an economic impact of more than $4 million annually."
Arguments in Opposition:
The California Nurses Association writes in opposition, "By shifting work that should be done by licensed and experienced personnel to unlicensed health care workers, [this bill] deskills this workforce and creates potential health risks. The total protein refractometer test is used prior to a donor undergoing plasmapheresis. Because of the risks involved in this procedure, both federal and state laws require that a donor's total protein level be tested in order to ensure the donor's safety and well-being. The total protein refractometer test helps detect underlying conditions that may cause complications. If the test is performed incorrectly, significant harm to donor patients could result…. Moreover, supporters have not demonstrated that there is a shortage of licensed and experienced personnel requiring this change in law. [This bill] is simply unnecessary. In addition, it is clear that manufacturers of digital refractometers and other businesses stand to gain financially by this bill. Donor patients, on the other hand, will lose."
FISCAL COMMENTS:
According to the Senate Appropriations Committee, pursuant to Senate Rule 28.8, no significant state costs anticipated.
VOTES:
ASM BUSINESS AND PROFESSIONS: 18-0-1
YES: Low, Brough, Arambula, Bloom, Chen, Cunningham, Eggman, Fong, Gipson, Gloria, Grayson, Holden, Irwin, McCarty, Medina, Mullin, Obernolte, Ting
ABS, ABST OR NV: Chiu
ASM APPROPRIATIONS: 18-0-0
YES: Gonzalez, Bigelow, Bauer-Kahan, Bloom, Bonta, Calderon, Carrillo, Chau, Megan Dahle, Diep, Eggman, Fong, Gabriel, Eduardo Garcia, Petrie-Norris, McCarty, Robert Rivas, Voepel
ASSEMBLY FLOOR: 72-0-7
YES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Choi, Chu, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kamlager, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Mullin, Nazarian, O'Donnell, Obernolte, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wood, Rendon
ABS, ABST OR NV: Chiu, Friedman, Gonzalez, Kalra, Muratsuchi, Quirk, Wicks
SENATE FLOOR: 39-0-1
YES: Allen, Archuleta, Atkins, Bates, Beall, Borgeas, Bradford, Caballero, Chang, Dahle, Dodd, Durazo, Galgiani, Glazer, Lena Gonzalez, Grove, Hertzberg, Hill, Hueso, Hurtado, Jackson, Leyva, McGuire, Melendez, Mitchell, Monning, Moorlach, Morrell, Nielsen, Pan, Portantino, Roth, Rubio, Skinner, Stern, Umberg, Wieckowski, Wiener, Wilk
ABS, ABST OR NV: Jones
UPDATED:
VERSION: August 25, 2020
CONSULTANT: Vincent Chee / B. & P. / (916) 319-3301 FN: 0002810
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 2199 |
THIRD READING
Bill No: AB 2199
Author: Nazarian (D)
Amended: 8/25/20 in Senate
Vote: 21
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 9-0, 8/8/20
AYES: Glazer, Chang, Archuleta, Dodd, Galgiani, Hill, Leyva, Pan, Wilk
SENATE APPROPRIATIONS COMMITTEE: Senate Rule 28.8
ASSEMBLY FLOOR: 72-0, 6/8/20 - See last page for vote
SUBJECT: Healing arts: clinical laboratories
SOURCE: Plasma Protein Therapeutics Association
DIGEST:
This bill extends the authorization for laboratory personnel who meet specified requirements to perform a total protein test using a digital refractometer in a licensed plasma collection center in this state until January 1, 2023, and adds a clinical laboratory scientist as one of the personnel who can supervise the person.
Senate Floor Amendments of 8/25/20 add technical and clarifying language.
ANALYSIS:
Existing law:
- Provides for the licensure, registration, and regulation of clinical laboratories and various clinical laboratory personnel by the California Department of Public Health (CDPH), with specified exceptions. (Business and Professions Code (BPC) § 1200-1327)
- Defines, for purposes of state regulation of clinical laboratories, the following:
- “CLIA” means the federal Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. Sec. 263a; P.L. 100-578) and the regulations adopted thereunder by the federal Health Care Financing Administration and effective on January 1, 1994, or any later date, when adopted in California pursuant to subdivision (b) of Section 1208. (BPC § 1202.5(a))
- “Clinical laboratory” meant any place used, or any establishment or institution organized or operated, for the performance of clinical laboratory tests or examinations or the practical application of the clinical laboratory sciences. That application may include any means that applies the clinical laboratory sciences. (BPC § 1206(a)(8))
- Authorizes a person to perform a total protein test using a digital refractometer in a licensed plasma collection center in this state, as specified. (BPC § 1246.7(a))
- Specifies that the person may only perform the test, if CDPH, as part of its routine, fee-supported inspection of the licensed plasma collection center, including its review of personnel reports for licensed and unlicensed personnel and job descriptions of all center positions for a licensed plasma collection center, determines that certain conditions have been met, including training for the individual performing testing and supervision and practice protocols.
- Requires the digital refractometer used to perform a total protein test pursuant under this exemption to meet specified criteria. (BPC § 1246.7(b))
- Requires a licensed plasma collection center to assess the competency and performance of persons authorized to perform the total protein test pursuant to this authorization and to make any required information or test results available to CDPH, as specified. (BPC § 1246.7(c))
- Requires records of digital refractometer test results collected to be maintained for three years and made available to CDPH upon request. (BPC § 1246.7(d))
- Specifies that this authorization remains in effect only until January 1, 2021.
This bill:
- Extends the operation of the above provisions until January 1, 2023, thereby extending the application of a crime and the provisions that make the records described above confidential.
- Authorizes a total protein test to be performed under the supervision of a clinical laboratory scientist.
- Makes a technical change to the standardized procedures that may apply to the performance of a total protein test under these provisions, as specified.
- Makes other technical and clarifying changes.
Background
Federal and State Regulation of Plasma for Donor Safety. Source plasma is a biologic and product derived from blood so the process of collecting source plasma is regulated and licensed under federal and state biologics laws to ensure donor safety. (42 U.S. Code § 262; BPC §§ 1600-1630). When donors give plasma, they undergo plasmapheresis: a process where a donor gives blood, plasma is separated from the formed elements, and then that blood is returned to the donor. Given this process, federal and state biologics laws provide safety precautions for source plasma donations, including various testing, timing, and fatality reporting requirements. They also require that a plasma collection center test a donor’s total protein level, among other things, before undergoing plasmapheresis. (42 CFR §640.65(b)(1)(i); CCR, tit. 17, § 1025(b))
Federal and State Regulation for Clinical Laboratory Testing. A facility that performs laboratory tests on human specimens for diagnosis or assessment must be certified under CLIA. CLIA certification requirements vary depending on the complexity of the laboratory tests performed. Clinical laboratories or other testing sites need to know whether each test system used is waived, moderate, or high complexity. In general, the more complicated the test, the more stringent the requirements, including increased training and licensing of laboratory personnel. At a minimum, all laboratories must have a licensed clinical laboratory director. While CLIA establishes minimum federal standards, it allows states to enact more stringent state law requirements. At the federal level and in California, anyone may perform a waived test in a licensed laboratory. For moderate complexity tests, federal law requires that, at a minimum, personnel have (1) a high school diploma or equivalent and (2) documentation of training appropriate for the testing performed prior to analyzing patient specimens. However, in California, only specified licensed, certified, or otherwise authorized individuals may perform moderate complexity tests. There are two exceptions allowing unlicensed individuals to perform a moderate complexity test in California. One is for anyone performing a blood gas analysis under BPC Section 1245 and anyone in a physician’s office laboratory with a physician readily available.
Total Protein Digital Refractometer Test. According to information provided by the author, donor centers typically use a digital refractometer to perform the total protein test. FDA considers the refractometer as a moderate complexity test. There are multiple types of protein refractometer devices, ranging from manual to automatic and handheld to benchtop. Depending on the device, the rest requires varying, small samples of blood from the donor, which is then placed into the device. Generally, a manual device requires the user to analyze the sample and calculate the result. An automatic device performs the analysis without input from the user and displays the result, which the user then compares to a set of standard guidelines for total protein levels. The FDA’s medical device database shows that the FDA has classified all total protein refractometer devices as of moderate complexity under CLIA…the total protein test helps to detect underlying conditions that may cause complications.
CDPH and Extending the Existing Pilot Program. Until 2018, state law required that the refractometer test be performed by various licensed personnel, such as a registered nurse or a clinical laboratory scientist, because the test is classified as a moderate complexity test under federal law. AB 613 (Nazarian, Chapter 799, Statutes of 2018) established a pilot program in order to demonstrate that an unlicensed individual could safely conduct a refractometer test. The pilot program, now codified into law, allows anyone with a high school diploma to carry out the test, as long as that person has completed certain training requirements. The program sunsets at the beginning of 2021.
Current Licensing Requirements for Operating a Refractometer. Under current state law, a person performing a total protein test must be supervised by a licensed individual who is available for consultation while the individual is processing specimens. These licensed individuals can be a moderate complexity laboratory technical consultant, a licensed registered nurse, a licensed physician or surgeon, or a clinical laboratory director. This bill adds a clinical laboratory scientists to the list of licensed professionals who can supervise an individual running the test. Of the professionals listed, moderate complexity laboratory technical consultants have the most comparable training and experience to clinical laboratory scientists. However, there are important differences in training and experience between the two. Moderate clinical laboratory technical consultants must have an active license in California to perform high complexity testing or to practice medicine, osteopathy or podiatry. They also must have a minimum of two years of experience in moderate or high complexity testing in the specialty or specialties in which they are consulting. They are also generally responsible for the technical and scientific oversight of the laboratory.
In contrast, a clinical laboratory scientist is licensed to engage in clinical laboratory practice under the supervision of a clinical laboratory director. A person licensed as a clinical laboratory scientist and qualified under CLIA may perform clinical laboratory tests or examinations classified as of high or moderate complexity under CLIA. This means that clinical laboratory scientists: (1) are not licensed medical professionals whereas moderate complexity laboratory technical consultants may be, (2) are not required to have two years of experience in the field, and (3) do not have the training for a good understanding of the technical and scientific oversight of a laboratory.
Plasma Donation and COVID-19. The sponsors of this bill report that they are developing potential treatments for COVID-19 patients using plasma donated by individuals who have recovered from COVID-19. The goal is to use the antibodies found in the collected manufacture of hyperimmune globulins to treat COVID-19 patients. The convalescent plasma is being collected at licensed plasma donation centers in the United States, including California.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
Plasma Protein Therapeutics Association (source)
Biocom
Cigna
Grifols, Inc.
Immune Deficiency Foundation
Takeda Pharmaceuticals America
The American Plasma Users Coalition
OPPOSITION: (Verified 8/25/20)
California Nurses Association
ARGUMENTS IN SUPPORT: Generally, supporters argue that the pilot program has provided data showing that properly trained, but unlicensed individuals are able to satisfactorily perform the total protein test with no harm to the potential donor. They argue extending the pilot program during COVID-19 makes sense so that the program can continue and so that plasma centers can be ready in the event that scientists develop a plasma therapy treatment for COVID-19.
ARGUMENTS IN OPPOSITION: The California Nurses Association argues that AB 2199 deskills the workforce and creates potential health risks, noting that “supporters have not demonstrated that there is a shortage of licensed and experienced personnel requiring this change in law. AB 2199 is simply unnecessary.”
ASSEMBLY FLOOR: 72-0, 6/8/20
AYES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Choi, Chu, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kamlager, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Mullin, Nazarian, Obernolte, O'Donnell, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wood, Rendon
NO VOTE RECORDED: Chiu, Friedman, Gonzalez, Kalra, Muratsuchi, Quirk, Wicks
Prepared by: Dana Shaker / B., P. & E.D. /
8/26/20 15:01:00
**** END ****
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 2199 |
THIRD READING
Bill No: AB 2199
Author: Nazarian (D)
Amended: 5/18/20 in Assembly
Vote: 21
SENATE BUS., PROF. & ECON. DEV. COMMITTEE: 9-0, 8/8/20
AYES: Glazer, Chang, Archuleta, Dodd, Galgiani, Hill, Leyva, Pan, Wilk
SENATE APPROPRIATIONS COMMITTEE: Senate Rule 28.8
ASSEMBLY FLOOR: 72-0, 6/8/20 - See last page for vote
SUBJECT: Healing arts: clinical laboratories
SOURCE: Plasma Protein Therapeutics Association
DIGEST:
This bill extends the authorization for laboratory personnel who meet specified requirements to perform a total protein test using a digital refractometer in a licensed plasma collection center in this state until January 1, 2023, and adds a clinical laboratory scientist as one of the personnel who can supervise the person.
ANALYSIS:
Existing law:
- Provides for the licensure, registration, and regulation of clinical laboratories and various clinical laboratory personnel by the California Department of Public Health (CDPH), with specified exceptions. (Business and Professions Code (BPC) § 1200-1327)
- Defines, for purposes of state regulation of clinical laboratories, the following:
- “CLIA” means the federal Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. Sec. 263a; P.L. 100-578) and the regulations adopted thereunder by the federal Health Care Financing Administration and effective on January 1, 1994, or any later date, when adopted in California pursuant to subdivision (b) of Section 1208. (BPC § 1202.5(a))
- “Clinical laboratory” meant any place used, or any establishment or institution organized or operated, for the performance of clinical laboratory tests or examinations or the practical application of the clinical laboratory sciences. That application may include any means that applies the clinical laboratory sciences. (BPC § 1206(a)(8))
- Authorizes a person to perform a total protein test using a digital refractometer in a licensed plasma collection center in this state, as specified. (BPC § 1246.7(a))
- Specifies that the person may only perform the test, if CDPH, as part of its routine, fee-supported inspection of the licensed plasma collection center, including its review of personnel reports for licensed and unlicensed personnel and job descriptions of all center positions for a licensed plasma collection center, determines that certain conditions have been met, including training for the individual performing testing and supervision and practice protocols.
- Requires the digital refractometer used to perform a total protein test pursuant under this exemption to meet specified criteria. (BPC § 1246.7(b))
- Requires a licensed plasma collection center to assess the competency and performance of persons authorized to perform the total protein test pursuant to this authorization and to make any required information or test results available to CDPH, as specified. (BPC § 1246.7(c))
- Requires records of digital refractometer test results collected to be maintained for three years and made available to CDPH upon request. (BPC § 1246.7(d))
- Specifies that this authorization remains in effect only until January 1, 2021.
This bill:
- Extends the operation of the above provisions until January 1, 2023, thereby extending the application of a crime and the provisions that make the records described above confidential.
- Authorizes a total protein test to be performed under the supervision of a clinical laboratory scientist.
- Makes a technical change to the standardized procedures that may apply to the performance of a total protein test under these provisions, as specified.
- Makes other technical and clarifying changes.
Background
Federal and State Regulation of Plasma for Donor Safety. Source plasma is a biologic and product derived from blood so the process of collecting source plasma is regulated and licensed under federal and state biologics laws to ensure donor safety. (42 U.S. Code § 262; BPC §§ 1600-1630). When donors give plasma, they undergo plasmapheresis: a process where a donor gives blood, plasma is separated from the formed elements, and then that blood is returned to the donor. Given this process, federal and state biologics laws provide safety precautions for source plasma donations, including various testing, timing, and fatality reporting requirements. They also require that a plasma collection center test a donor’s total protein level, among other things, before undergoing plasmapheresis. (42 CFR §640.65(b)(1)(i); CCR, tit. 17, § 1025(b))
Federal and State Regulation for Clinical Laboratory Testing. A facility that performs laboratory tests on human specimens for diagnosis or assessment must be certified under CLIA. CLIA certification requirements vary depending on the complexity of the laboratory tests performed. Clinical laboratories or other testing sites need to know whether each test system used is waived, moderate, or high complexity. In general, the more complicated the test, the more stringent the requirements, including increased training and licensing of laboratory personnel. At a minimum, all laboratories must have a licensed clinical laboratory director. While CLIA establishes minimum federal standards, it allows states to enact more stringent state law requirements. At the federal level and in California, anyone may perform a waived test in a licensed laboratory. For moderate complexity tests, federal law requires that, at a minimum, personnel have (1) a high school diploma or equivalent and (2) documentation of training appropriate for the testing performed prior to analyzing patient specimens. However, in California, only specified licensed, certified, or otherwise authorized individuals may perform moderate complexity tests. There are two exceptions allowing unlicensed individuals to perform a moderate complexity test in California. One is for anyone performing a blood gas analysis under BPC Section 1245 and anyone in a physician’s office laboratory with a physician readily available.
Total Protein Digital Refractometer Test. According to information provided by the author, donor centers typically use a digital refractometer to perform the total protein test. FDA considers the refractometer as a moderate complexity test. There are multiple types of protein refractometer devices, ranging from manual to automatic and handheld to benchtop. Depending on the device, the rest requires varying, small samples of blood from the donor, which is then placed into the device. Generally, a manual device requires the user to analyze the sample and calculate the result. An automatic device performs the analysis without input from the user and displays the result, which the user then compares to a set of standard guidelines for total protein levels. The FDA’s medical device database shows that the FDA has classified all total protein refractometer devices as of moderate complexity under CLIA…the total protein test helps to detect underlying conditions that may cause complications.
CDPH and Extending the Existing Pilot Program. Until 2018, state law required that the refractometer test be performed by various licensed personnel, such as a registered nurse or a clinical laboratory scientist, because the test is classified as a moderate complexity test under federal law. AB 613 (Nazarian, Chapter 799, Statutes of 2018) established a pilot program in order to demonstrate that an unlicensed individual could safely conduct a refractometer test. The pilot program, now codified into law, allows anyone with a high school diploma to carry out the test, as long as that person has completed certain training requirements. The program sunsets at the beginning of 2021.
Current Licensing Requirements for Operating a Refractometer. Under current state law, a person performing a total protein test must be supervised by a licensed individual who is available for consultation while the individual is processing specimens. These licensed individuals can be a moderate complexity laboratory technical consultant, a licensed registered nurse, a licensed physician or surgeon, or a clinical laboratory director. This bill adds a clinical laboratory scientists to the list of licensed professionals who can supervise an individual running the test. Of the professionals listed, moderate complexity laboratory technical consultants have the most comparable training and experience to clinical laboratory scientists. However, there are important differences in training and experience between the two. Moderate clinical laboratory technical consultants must have an active license in California to perform high complexity testing or to practice medicine, osteopathy or podiatry. They also must have a minimum of two years of experience in moderate or high complexity testing in the specialty or specialties in which they are consulting. They are also generally responsible for the technical and scientific oversight of the laboratory.
In contrast, a clinical laboratory scientist is licensed to engage in clinical laboratory practice under the supervision of a clinical laboratory director. A person licensed as a clinical laboratory scientist and qualified under CLIA may perform clinical laboratory tests or examinations classified as of high or moderate complexity under CLIA. This means that clinical laboratory scientists: (1) are not licensed medical professionals whereas moderate complexity laboratory technical consultants may be, (2) are not required to have two years of experience in the field, and (3) do not have the training for a good understanding of the technical and scientific oversight of a laboratory.
Plasma Donation and COVID-19. The sponsors of this bill report that they are developing potential treatments for COVID-19 patients using plasma donated by individuals who have recovered from COVID-19. The goal is to use the antibodies found in the collected manufacture of hyperimmune globulins to treat COVID-19 patients. The convalescent plasma is being collected at licensed plasma donation centers in the United States, including California.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
SUPPORT: (Verified 8/18/20)
Plasma Protein Therapeutics Association (source)
Biocom
Cigna
Grifols, Inc.
Immune Deficiency Foundation
Takeda Pharmaceuticals America
The American Plasma Users Coalition
OPPOSITION: (Verified 8/18/20)
California Nurses Association
ARGUMENTS IN SUPPORT: Generally, supporters argue that the pilot program has provided data showing that properly trained, but unlicensed individuals are able to satisfactorily perform the total protein test with no harm to the potential donor. They argue extending the pilot program during COVID-19 makes sense so that the program can continue and so that plasma centers can be ready in the event that scientists develop a plasma therapy treatment for COVID-19.
ARGUMENTS IN OPPOSITION: The California Nurses Association argues that AB 2199 deskills the workforce and creates potential health risks, noting that “supporters have not demonstrated that there is a shortage of licensed and experienced personnel requiring this change in law. AB 2199 is simply unnecessary.”
ASSEMBLY FLOOR: 72-0, 6/8/20
AYES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Choi, Chu, Cooley, Cooper, Cunningham, Megan Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kamlager, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Mullin, Nazarian, Obernolte, O'Donnell, Patterson, Petrie-Norris, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wood, Rendon
NO VOTE RECORDED: Chiu, Friedman, Gonzalez, Kalra, Muratsuchi, Quirk, Wicks
Prepared by: Dana Shaker / B., P. & E.D. /
8/19/20 10:49:42
**** END ****
SENATE COMMITTEE ON
BUSINESS, PROFESSIONS AND ECONOMIC DEVELOPMENT
Senator Steven Glazer, Chair
2019 - 2020 Regular
Bill No: AB 2199 Hearing Date: August 8, 2020
Author: | Nazarian | ||
Version: | May 18, 2020 | ||
Urgency: | No | Fiscal: | Yes |
Consultant: | Dana Shaker | ||
Subject: Healing arts: clinical laboratories
SUMMARY:
Extends the authorization for laboratory personnel who meet specified requirements to perform a total protein test using a digital refractometer in a licensed plasma collection center in this state until January 1, 2023, and adds a clinical laboratory scientist as one of the personnel who can supervise the person.
Existing law:
- Provides for the licensure, registration, and regulation of clinical laboratories and various clinical laboratory personnel by the California Department of Public Health (CDPH), with specified exceptions. (Business and Professions Code (BPC) § 1200-1327)
- Defines, for purposes of state regulation of clinical laboratories, the following:
- “CLIA” means the federal Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. Sec. 263a; P.L. 100-578) and the regulations adopted thereunder by the federal Health Care Financing Administration and effective on January 1, 1994, or any later date, when adopted in California pursuant to subdivision (b) of Section 1208. (BPC § 1202.5(a))
- “Clinical laboratory” meant any place used, or any establishment or institution organized or operated, for the performance of clinical laboratory tests or examinations or the practical application of the clinical laboratory sciences. That application may include any means that applies the clinical laboratory sciences. (BPC § 1206(a)(8))
- Authorizes a person to perform a total protein test using a digital refractometer in a licensed plasma collection center in this state, as specified. (BPC § 1246.7(a))
- Specifies that the person may only perform the test, if CDPH, as part of its routine, fee-supported inspection of the licensed plasma collection center, including its review of personnel reports for licensed and unlicensed personnel and job descriptions of all center positions for a licensed plasma collection center, determines that the following conditions are met:
- The person has earned a high school diploma or equivalent, as determined by the federal Centers for Medicare and Medicaid Services (CMS) pursuant to the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA). (42 U.S.C. Sec. 263a) (BPC § 1246.7(a)(1)(A))
- The person has training sufficient to demonstrate that the individual has the skills and abilities required of unlicensed laboratory personnel performing CLIA testing, as specified. (BPC § 1246.7(a)(1)(B))
- In addition to the education and training requirements specified above, the person has received five hours of training in the proper procedures to be employed when performing a total protein test using a digital refractometer and the procedures for recording the test results, as specified. (BPC § 1246.7(a)(2)(A))
- The person’s training in the proper procedure to be employed when performing a total protein test using a digital refractometer has been certified by a moderate complexity laboratory technical consultant as specified, by a physician and surgeon licensed in this state, or by a licensed clinical laboratory director who is in charge of the licensed plasma collection center. (BPC § 1246.7(a)(2)(B))
- The instructor documents, and the plasma collection center maintains the documentation of, the individual’s successful completion of training in the performance of the total protein test using a digital refractometer. This documentation must be made available to CDPH upon request. (BPC § 1246.7(a)(2)(C))
- The person performs the total protein test using a digital refractometer under the supervision of one of the authorized individuals who is physically onsite in the licensed plasma collection center and is available for consultation and direction while the person is processing specimens and performing the test. (BPC § 1246.7(a)(3))
- Authorizes the following individuals to supervise the person:
- A moderate complexity laboratory technical consultant, as specified. (BPC § 1246.7(a)(3)(A))
- A licensed registered nurse. (BPC § 1246.7(a)(3)(B))
- A licensed physician or surgeon. (BPC § 1246.7(a)(3)(C))
- A clinical laboratory director licensed pursuant to this chapter. (BPC § 1246.7(a)(3)(D))
- The person performs the total protein test using a digital refractometer in accordance with (1) standardized operating procedures required by the licensed plasma collection center’s license and (2) standardized procedures developed and approved by the licensed plasma collection center’s supervising physician and surgeon or licensed clinical laboratory director for administration of the total protein test by the persons authorized to perform the total protein test pursuant to this section. These standardized procedures must be made available to the CDPH upon request. (BPC § 1246.7(a)(4))
- The person does not draw the blood sample required for the test using a procedure that requires a registration, certification, or license under state law unless the person is properly registered, certified, or licensed to perform the procedure. (BPC § 1246.7(a)(5))
- The person’s competency in performing total protein tests using a digital refractometer is evaluated before testing on donors, and again every six months, by the CLIA lab director or technical consultant by direct observation. A licensed plasma collection center must maintain documentation of the competency evaluation, which must be made available to CDPH upon request. (BPC § 1246.7((a)(6))
- The person accurately records the results of the total protein test in a federal FDA 510k-approved blood establishment computer system (BECS), which must be verified. (BPC § 1246.7(a)(7))
- The person’s results are verified in one of the following ways:
- Using a digital refractometer that creates an electronic record of the test results. (BPC § 1246.7(a)(7)(A))
- Having each record entered by the individual verified for accuracy at the time the test result is recorded and while the result remains visible on the digital refractometer by a registered nurse or by the individual who is supervising the individual performing the test. The individual certifying the accuracy shall affix their name to the record verifying the accuracy of the entries. (BPC § 1246.7(a)(7)(B))
- Affixing a date- and time-stamped photograph of the digital refractometer test results to the spreadsheet. (BPC § 1246.7(a)(7)(C))
- The plasma collection center utilizing a double blind computer entry system that requires the test results to be accurately entered into the record twice before the results are recorded as final. (BPC § 1246.7(a)(7)(D))
- Requires the digital refractometer used to perform a total protein test pursuant under this exemption to meet specified criteria. (BPC § 1246.7(b))
- Requires a licensed plasma collection center to assess the competency and performance of persons authorized to perform the total protein test pursuant to this authorization and to make any required information or test results available to CDPH, as specified. (BPC § 1246.7(c))
- Requires records of digital refractometer test results collected to be maintained for three years and made available to CDPH upon request. (BPC § 1246.7(d))
- Specifies that this authorization remains in effect only until January 1, 2021.
This bill:
- Extends the operation of the above provisions until January 1, 2023, thereby extending the application of a crime and the provisions that make the records described above confidential.
- Authorizes a total protein test to be performed under the supervision of a clinical laboratory scientist.
- Makes a technical change to the standardized procedures that may apply to the performance of a total protein test under these provisions, as specified.
- Makes other technical and clarifying changes.
FISCAL EFFECT:
According to Assembly Committee on Appropriations, this bill will result in minor and absorbable costs to CDPH to continue oversight of this exemption.
COMMENTS:
- Purpose. The Plasma Protein Therapeutics Association is the Sponsor of this
bill. According to the author, “By allowing trained and qualified plasma donation centers employees to perform the total protein test with a digital refractometer, AB 2199 will make sure four things: 1) licensed individuals are utilized to the highest level of their job skills resulting in more efficient source plasma donor screening; 2) it will ensure appropriate controls are in place for the digital refractometer to maintain continued donor safety when a Total Protein Test is administered; 3) bring California in line with the majority of other states that allow a Total Protein Test to be administered this way and; 4) will ensure Californians with rare disease have appropriate access to the “lifesaving drug” that plasma proteins therapies provide.”
- Background.
Federal and State Regulation of Plasma for Donor Safety. Source plasma is a biologic and product derived from blood so the process of collecting source plasma is regulated and licensed under federal and state biologics laws to ensure donor safety. (42 U.S. Code § 262; BPC §§ 1600-1630). When donors give plasma, they undergo plasmapheresis: a process where a donor gives blood, plasma is separated from the formed elements, and then that blood is returned to the donor. Given this process, federal and state biologics laws provide safety precautions for source plasma donations, including various testing, timing, and fatality reporting requirements. They also require that a plasma collection center test a donor’s total protein level, among other things, before undergoing plasmapheresis. (42 CFR §640.65(b)(1)(i); CCR, tit. 17, § 1025(b))
Federal and State Regulation for Clinical Laboratory Testing. A facility that performs laboratory tests on human specimens for diagnosis or assessment must be certified under CLIA. CLIA certification requirements vary depending on the complexity of the laboratory tests performed.
Clinical laboratories or other testing sites need to know whether each test system used is waived, moderate, or high complexity. In general, the more complicated the test, the more stringent the requirements, including increased training and licensing of laboratory personnel. At a minimum, all laboratories must have a licensed clinical laboratory director…The FDA determines the complexity of CLIA laboratory tests. Waived tests are simple tests with a low risk for an incorrect result. They include tests listed in the CLIA regulations, tests cleared by the FDA for home use, and tests approved for waiver by the FDA using the CLIA criteria. Tests not classified as waived are assigned a moderate or high complexity category based on seven criteria given in the CLIA regulations, including ease of use, knowledge required, and types of materials tested. For commercially available FDA-cleared or approved tests, the test complexity is determined by the FDA during the pre-market approval process.
While CLIA establishes minimum federal standards, it allows states to enact more stringent state law requirements. At the federal level and in California, anyone may perform a waived test in a licensed laboratory. For moderate complexity tests, federal law requires that, at a minimum, personnel have 1) a high school diploma or equivalent and 2) documentation of training appropriate for the testing performed prior to analyzing patient specimens. However, in California, only specified licensed, certified, or otherwise authorized individuals may perform moderate complexity tests. There are two exceptions allowing unlicensed individuals to perform a moderate complexity test in California. One is for anyone performing a blood gas analysis under BPC § 1245 and anyone in a physician’s office laboratory with a physician readily available.”
Total Protein Digital Refractometer Test. According to information provided by the author, donor centers typically use a digital refractometer to perform the total protein test. FDA considers the refractometer as a moderate complexity test. There are multiple types of protein refractometer devices, ranging from manual to automatic and handheld to benchtop. Depending on the device, the rest requires varying, small samples of blood from the donor, which is then placed into the device. Generally, a manual device requires the user to analyze the sample and calculate the result. An automatic device performs the analysis without input from the user and displays the result, which the user then compares to a set of standard guidelines for total protein levels. The FDA’s medical device database shows that the FDA has classified all total protein refractometer devices as of moderate complexity under CLIA…the total protein test helps to detect underlying conditions that may cause complications.
CDPH and Extending the Existing Pilot Program. Until 2018, state law required that the refractometer test be performed by various licensed personnel, such as a registered nurse or a clinical laboratory scientist, because the test is classified as a moderate complexity test under federal law. In 2015, AB 757 (Gomez of 2015) was introduced to authorize a person who met certain criteria to perform a total protein refractometer test using an automatic, button-operated refractometer with a digital readout in a licensed plasma collection facility in this state. Governor Brown vetoed the bill, stating that “f]ailure to perform and report this test accurately could lead to serious health consequences for the donor. The California Department of Public Health does not believe that the standards outlined in the bill for persons to perform this test ensure the health and safety of plasma donors.”
In response, AB 613 (Nazarian, Chapter 799, Statutes of 2018) established a pilot program in order to demonstrate that an unlicensed individual could safely conduct a refractometer test. The pilot program, now codified into law, allows anyone with a high school diploma to carry out the test, as long as that person has completed certain training requirements. The program sunsets at the beginning of 2021.
This bill would extend this pilot program by two years, allowing an unlicensed individual to perform a total protein test using a digital refractometer during the donor screening process at plasma donation centers until January 1, 2023. As they did for AB 613 in 2018, the sponsors of this bill argue that individuals conducting a digital refractometer test only need the current level of education and training outlined in the existing pilot program, rather than the previously-imposed standard.
Current Licensing Requirements for Operating a Refractometer. Under current state law, a person performing a total protein test must be supervised by a licensed individual who is available for consultation while the individual is processing specimens. These licensed individuals can be a moderate complexity laboratory technical consultant, a licensed registered nurse, a licensed physician or surgeon, or a clinical laboratory director. This bill would add a clinical laboratory scientists to the list of licensed professionals who can supervise an individual running the test.
Of the professionals listed, moderate complexity laboratory technical consultants have the most comparable training and experience to clinical laboratory scientists. However, there are important differences in training and experience between the two. Moderate clinical laboratory technical consultants must have an active license in California to perform high complexity testing or to practice medicine, osteopathy or podiatry. They also must have a minimum of two years of experience in moderate or high complexity testing in the specialty or specialties in which they are consulting. They are also generally responsible for the technical and scientific oversight of the laboratory.
In contrast, a clinical laboratory scientist is licensed to engage in clinical laboratory practice under the supervision of a clinical laboratory director. A person licensed as a clinical laboratory scientist and qualified under CLIA may perform clinical laboratory tests or examinations classified as of high or moderate complexity under CLIA. This means that clinical laboratory scientists: 1) are not licensed medical professionals whereas moderate complexity laboratory technical consultants may be, 2) are not required to have two years of experience in the field, and 3) do not have the training for a good understanding of the technical and scientific oversight of a laboratory.
Plasma Donation and COVID-19. The sponsors of this bill report that they are developing potential treatments for COVID-19 patients using plasma donated by individuals who have recovered from COVID-19. The goal is to use the antibodies found in the collected manufacture of hyperimmune globulins to treat COVID-19 patients. The convalescent plasma is being collected at licensed plasma donation centers in the United States, including California.
- Prior Related Legislation. AB 613 (Nazarian, Chapter 799, Statutes of 2018) authorized an unlicensed individual who meets specified education and training requirements to perform a total protein test using a digital refractometer in a licensed plasma collection facility until January 1, 2021.
AB 757 (Gomez of 2015) would have authorized a person, who met specified criteria, to perform a total protein refractometer test using an automatic, button-operated refractometer with a digital readout in a licensed plasma collection facility in this state. This bill was vetoed by Governor Brown, who stated that “[f]ailure to perform and report this test accurately could lead to serious health consequences for the donor. The California Department of Public Health does not believe that the standards outlined in the bill for persons to perform this test ensure the health and safety of plasma donors.”
- Arguments in Support. Biocom writes in support: “Plasma therapy is an important
element in many treatments, including hemophilia and several immunological diseases. It has also been widely discussed as a promising candidate for use as a treatment in the fight against COVID-19 in multiple ways. AB 2199 will facilitate significantly more plasma collection to occur in California, which is already home to significant research in this field.”
Cigna writes in support noting that its “specialty pharmacy, Accredo, provides specialty services to patients that need Immunoglobulin Therapy (IG) delivered in their home by its team of nurses. IG is obtained from a part of human blood called plasma. During production, the plasma is tested to make sure it is free from agents that may cause infection. Therefore, it’s important that we continue to have plasma donation centers collecting and testing blood for protein levels so our patients have access to medicines and therapies that may save their lives. We are not aware of any quality of care concerns issues arising out of the existing pilot program that has been operating for a number of years in California. Moreover, the current practice of training personal and maintaining clinical oversight ensures that these donation centers are operating in a safe, efficient and effective manner.”
Immune Deficiency Foundation states that “California is home to only a handful of plasma donation centers, largely due to burdensome regulations. These regulations prevent licensed professionals from being utilized to the highest level of their job skills, resulting in less efficient source plasma donor screening. The lack of efficiency and minimal presence of plasma donation centers in California creates a reliance on plasma collection elsewhere and contributes to the strain on the global plasma supply. The need for plasma and plasma-derived products grows each year, for the PI community as well as globally, and updating the governance around plasma donation in California can help address that need. IDF believes that extending the pilot program in question is a step in this direction, and that it will demonstrate more efficient plasma collection in California, without compromised safety for plasma donors or users.”
According to Grifols, Inc. “In 2018, the California Legislature passed legislation to create a pilot to determine if a properly trained individual may satisfactorily perform a total protein test using a digital refractometer in a licensed plasma collection center. This is the federal standard followed in most of the 44 states where plasma is collected. Grifols was fortunate to have 5 plasma collection centers participate in the pilot and the results have shown that the properly trained, but unlicensed individual is able to satisfactorily perform the total protein test with no harm to the potential donor. These results are not surprising since properly trained, but unlicensed individuals perform the total protein test using a digital refractometer in more than 800 source plasma donation centers in the United States. This test is performed to ensure an individual is suitable to donate source plasma on a given day.”
Takeda Pharmaceuticals America states that “The outbreak of COVID-19 provides one example of the critical need for plasma-derived therapies and for robust plasma collection. Takeda has announced the company’s participation in the CoVIg-19 Plasma Alliance which is an unprecedented partnership of world-leading plasma companies formed to meet the unprecedented challenge of COVID-19. The Alliance was established to accelerate the development of a potential plasma-derived hyperimmune globulin therapy for COVID-19. We will refer to the potential therapy as CoVIg-19. Alliance membership has expanded to include 10 plasma companies and now also includes global organizations from outside the plasma industry who are providing vital support to encourage more people to donate convalescent plasma (Microsoft, Google & Uber Health).”
The American Plasma Users Coalition (APLUS) believes that “the provisions found in AB 2199 will ensure that licensed professionals are utilized to the highest level of their job skills resulting in more efficient source plasma donor screening. It will free up specialized staff to perform other essential functions in these source plasma donation centers, such as conducting new donor physical examinations. This is critical because the growing clinical need for plasma medicines means we need more source plasma donations.”
The Plasma Protein Therapeutics Association writes in support: “Plasma donation center personnel perform the total protein test as part of the pre-donation screening of potential donors. The purpose of the test is to monitor the protein levels of frequent donors. Infrequent donors are allowed to donate without a total protein test. The protein test is not a donor safety issue. Pilot-operators have successfully performed more than 360,000 pilot tests. There were more than 50,000,000 tests performed last year in the states that follow CLIA standards which are the California pilot standards. The pilot has shown that the properly trained, but unlicensed individual is able to satisfactorily perform the total protein test with no harm to the potential donor.”
- Arguments in Opposition. The California Nurses Association writes in opposition:
“By shifting work that should be done by licensed and experienced personnel to unlicensed health care workers, AB 2199 deskills this workforce and creates potential health risks. The total protein refractometer test is used prior to a donor undergoing plasmapheresis. Because of the risks involved in this procedure, both federal and state laws require that a donor’s total protein level be tested in order to ensure the donor’s safety and well-being. The total protein refractometer test helps detect underlying conditions that may cause complications. If the test is performed incorrectly, significant harm to donor patients could results….Moreover, supporters have not demonstrated that there is a shortage of licensed and experienced personnel requiring this change in law. AB 2199 is simply unnecessary. In addition, it is clear that manufacturers of digital refractometers and other businesses stand to gain financially by this bill. Donor patients, on the other hand, will lose.”
- Policy Considerations.
COVID-19. COVID-19 has dramatically shifted policy priorities at the local, state, federal, and global levels, particularly in the healthcare industry. With scientists in a race for a cure, there is a desire to increase laboratories and centers that could potentially house and distribute a medical remedy. The sponsors of the bill have argued that increasing plasma centers could be crucial in distributing a plasma-based COVID-19 cure, and they report they have been developing a potential COVID-19 treatment. However, there is no evidence to suggest that a plasma therapeutic will appear on the market at this time. Additionally, those wishing to build and operate plasma centers in California are currently able to do so under existing law, and the COVID-19 crisis has taken a toll on the employees and resources of CDPH in particular. Therefore, while the intention to lay the groundwork for distribution of a COVID-19 cure is a good one, there are questions as to whether this legislation is necessary at this particular moment.
Qualified Personnel and Shortage of Personnel? With the data at CDPH still under review, it is currently unclear whether the pilot program has definitely proven what it set out to accomplish. The sponsors claim it has, stating that “[p]ilot-operators have successfully performed more than 360,000 pilot tests. There were more than 50,000,000 tests performed last year in the states that follow CLIA standards which are the California pilot standards.” Opposition states there are still risks involved in the procedure, which is the reason why federal and state law required higher educational and experiential standards, and that “supporters have not demonstrated that there is a shortage of licensed and experienced personnel requiring this change in law.” While changing existing law at this time by not extending the sunset date could create more confusion, it is also compelling that there is currently no demonstrated shortage of licensed and experienced personnel. The data from CDPH will provide important information to lay the groundwork for the path forward.
Are Experienced Supervisors Necessary? The fact that there are required experiential differences between a moderate complexity laboratory technical consultant—let alone a registered nurse, physician, or surgeon—and a clinical laboratory scientist as a supervisor should be noted when considering this bill. While supporters argue that none of these elements are necessary for the refractometer test supervised individuals are conducting, requiring years of experience supervising a particular test seems to be an important asset in ensuring donor safety and preventative measures/caution, especially in these COVID-19 times when the normal procedure protocols are changing.
SUPPORT AND OPPOSITION:
Support:
The Plasma Protein Therapeutics Association (sponsor)
Biocom
Cigna
Grifols, Inc.
Immune Deficiency Foundation
Takeda Pharmaceuticals America
The American Plasma Users Coalition
Opposition:
California Nurses Association
-- END –
ASSEMBLY THIRD READING
ATR Bill Id:AB 2199
Author:(Nazarian)
As Amended Ver:May 18, 2020
Majority vote
SUMMARY:
Extends the authorization for laboratory personnel who meet specified requirements to perform a total protein test using a digital refractometer in a licensed plasma collection center in this state until January 1, 2023, and adds a clinical laboratory scientist as one of the personnel who can supervise the person.
Major Provisions
COMMENTS:
Background. This bill would extend an exemption under California clinical laboratory testing requirements by two years, allowing an unlicensed individual to perform a total protein test using a digital refractometer during the donor screening process at plasma donation centers until January 1, 2023. The sponsor of this bill represents private sector manufacturers of plasma protein therapies and collectors of source plasma. According to the sponsor, plasma protein therapies are used to treat medical conditions resulting from insufficient levels of plasma protein, including immune deficiencies and bleeding disorders.
Plasma Donation and COVID-19. The sponsors of this bill report that they are developing potential treatments for COVID-19 patients using plasma donated by individuals who have recovered from COVID-19. The goal is to use the antibodies found in the collected manufacture of hyperimmune globulins to treat COVID-19 patients. The convalescent plasma is being collected at licensed plasma donation centers in the United States, including California.
According to the Author:
"By allowing trained and qualified plasma donation centers employees to perform the total protein test with a digital refractometer, [this bill] will make sure four things: 1) licensed individuals are utilized to the highest level of their job skills resulting in more efficient source plasma donor screening; 2) it will ensure appropriate controls are in place for the digital refractometer to maintain continued donor safety when a Total Protein Test is administered; 3) bring California in line with the majority of other states that allow a Total Protein Test to be administered this way and; 4) will ensure Californians with rare disease have appropriate access to the 'lifesaving drug' that plasma proteins therapies provide."
Arguments in Support:
The Plasma Protein Therapeutics Association writes in support, "In 2018, The California Legislature passed legislation to create a pilot to determine if a properly trained individual may satisfactorily perform a total protein test using a digital refractometer in a licensed plasma collection center. This is the federal standard followed in most of the 44 states where plasma is donated.
The pilot has shown that the properly trained, but unlicensed individual is able to satisfactorily perform the total protein test with no harm to the potential donor. These results are not surprising since properly trained but unlicensed individuals perform the total protein test using a digital refractometer in more than 800 source plasma donation centers in the United States. The test is done to make sure an individual is suitable to donate source plasma on a given day.
[This bill] will ensure that licensed professionals are utilized to the highest level of their job skills resulting in more efficient source plasma donor screening. It will free up specialized staff to perform other essential functions in these source plasma donation centers, such as conducting new donor physical examinations. This is critical because the growing clinical need for plasma medicines means we need more source plasma donations. It takes more than 130 source plasma donations to manufacture the Ig needed annually to treat an individual with primary immune deficiency….
This is where California may make a difference. California currently has 26 source plasma donation centers. This is a result of laws that are not conducive to source plasma donation. For comparison, there are more than 100 source plasma donation centers in Texas, more than 60 in Florida, and more than 40 in Ohio…. Plasma donation centers benefit the communities they are in by providing good jobs to more than 50 employees per center and an economic impact of more than $4 million annually."
Arguments in Opposition:
The California Nurses Association writes in opposition, "By shifting work that should be done by licensed and experienced personnel to unlicensed health care workers, [this bill] deskills this workforce and creates potential health risks. The total protein refractometer test is used prior to a donor undergoing plasmapheresis. Because of the risks involved in this procedure, both federal and state laws require that a donor's total protein level be tested in order to ensure the donor's safety and well-being. The total protein refractometer test helps detect underlying conditions that may cause complications. If the test is performed incorrectly, significant harm to donor patients could result…. Moreover, supporters have not demonstrated that there is a shortage of licensed and experienced personnel requiring this change in law. [This bill] is simply unnecessary. In addition, it is clear that manufacturers of digital refractometers and other businesses stand to gain financially by this bill. Donor patients, on the other hand, will lose."
FISCAL COMMENTS:
According to the Assembly Appropriations Committee, minor and absorbable costs to California Department of Public Health (CDPH) to continue oversight of this exemption (Licensing and Certification Fund).
VOTES:
ASM BUSINESS AND PROFESSIONS: 18-0-1
YES: Low, Brough, Arambula, Bloom, Chen, Cunningham, Eggman, Fong, Gipson, Gloria, Grayson, Holden, Irwin, McCarty, Medina, Mullin, Obernolte, Ting
ABS, ABST OR NV: Chiu
ASM APPROPRIATIONS: 18-0-0
YES: Gonzalez, Bigelow, Bauer-Kahan, Bloom, Bonta, Calderon, Carrillo, Chau, Megan Dahle, Diep, Eggman, Fong, Gabriel, Eduardo Garcia, Petrie-Norris, McCarty, Robert Rivas, Voepel
UPDATED:
VERSION: May 18, 2020
CONSULTANT: Vincent Chee / B. & P. / (916) 319-3301 FN: 0002810
Date of Hearing: June 2, 2020
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
ABPCA Bill Id:AB 2199
Author:(Nazarian) – As Amended Ver:May 18, 2020
Policy Committee: | Business and Professions | Vote: | 18 - 0 |
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill extends the authorization for laboratory personnel who meet specified requirements to perform a total protein test using a digital refractometer in a licensed plasma collection center in this state until January 1, 2023, and adds a clinical laboratory scientist as one of the personnel who can supervise the laboratory personnel.
FISCAL EFFECT:
Minor and absorbable costs to California Department of Public Health (CDPH) to continue oversight of this exemption (Licensing and Certification Fund).
COMMENTS:
- Purpose. The author states this bill is necessary to continue a narrow exemption in the law to allow time for CDPH to assess safety data related to the exemption.
- Background. Federal and state law jointly govern the provision of laboratory services, and the CDPH regulates laboratories on behalf of the state and federal government. The Clinical Laboratory Improvement Amendments (CLIA), is the federal framework for laboratory oversight. Under CLIA, tests are classified as either waived, moderate-complexity or high-complexity. Waived tests are simple and low-risk, while moderate- and high-complexity tests are subject to more stringent regulation. Existing law authorizes certain exceptions from normal rules governing which professionals can conduct certain tests.
AB 613 (Nazarian), Chapter 799, Statutes of 2018, established the exemption this bill would extend for an additional two years. It allows unlicensed persons to perform a total protein test using a digital refractometer in a licensed plasma collection center. The test measures blood protein and is important for determining a donor’s eligibility. According to the sponsor, Plasma Protein Therapeutics Association, 48 other states allow this exemption. AB 613 had a sunset in order to allow CDPH to review safety data to inform whether the exemption should continue. According to CDPH, that data is still under review.
- Support and Opposition. The plasma industry and related advocacy organizations support this bill. Supporters indicate it will improve efficiency and even assert ending the exemption would result in more plasma centers being built, creating jobs and offering greater access to Californians to donate plasma. The California Nurses Association opposes this bill, citing concerns about safety and about “de-skilling” the nursing profession, as well as questioning the bill’s necessity.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing:
ASSEMBLY COMMITTEE ON BUSINESS AND PROFESSIONS
Evan Low, Chair
ABPCA Bill Id:AB 2199
Author:(Nazarian) – As Amended Ver:May 18, 2020
SUBJECT: Healing arts: clinical laboratories.
SUMMARY: Extends the authorization for laboratory personnel who meet specified requirements to perform a total protein test using a digital refractometer in a licensed plasma collection center in this state until January 1, 2023, and adds a clinical laboratory scientist as one of the personnel who can supervise the person.
EXISTING LAW:
- Provides for the licensure, registration, and regulation of clinical laboratories and various clinical laboratory personnel by the California Department of Public Health (CDPH), with specified exceptions. (BPC § 1200-1327)
- Defines, for purposes of state regulation of clinical laboratories, the following:
- “CLIA” means the federal Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. Sec. 263a; P.L. 100-578) and the regulations adopted thereunder by the federal Health Care Financing Administration and effective on January 1, 1994, or any later date, when adopted in California pursuant to subdivision (b) of Section 1208. (BPC § 1202.5(a))
- “Clinical laboratory” meant any place used, or any establishment or institution organized or operated, for the performance of clinical laboratory tests or examinations or the practical application of the clinical laboratory sciences. That application may include any means that applies the clinical laboratory sciences. (BPC § 1206(a)(8))
- Authorizes a person who to perform a total protein test using a digital refractometer in a licensed plasma collection center in this state, as specified. (BPC § 1246.7(a))
- Specifies that the person my only perform the test, if the CDPH, as part of its routine, fee-supported inspection of the licensed plasma collection center, including its review of personnel reports for licensed and unlicensed personnel and job descriptions of all center positions for a licensed plasma collection center, determines that the following conditions are met:
- The person has earned a high school diploma or equivalent, as determined by the federal Centers for Medicare and Medicaid Services (CMS) pursuant to the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA) (42 U.S.C. Sec. 263a). (BPC § 1246.7(a)(1)(A))
- The person has training sufficient to demonstrate that the individual has the skills and abilities required of unlicensed laboratory personnel performing CLIA testing, as specified. (BPC § 1246.7(a)(1)(B))
- In addition to the education and training requirements specified above, the person has received five hours of training in the proper procedures to be employed when performing a total protein test using a digital refractometer and the procedures for recording the test results, as specified. (BPC § 1246.7(a)(2)(A))
- The person’s training in the proper procedure to be employed when performing a total protein test using a digital refractometer has been certified by a moderate complexity laboratory technical consultant as specified, by a physician and surgeon licensed in this state, or by a licensed clinical laboratory director who is in charge of the licensed plasma collection center. (BPC § 1246.7(a)(2)(B))
- The instructor documents, and the plasma collection center maintains the documentation of, the individual’s successful completion of training in the performance of the total protein test using a digital refractometer. This documentation must be made available to the CDPH upon request. (BPC § 1246.7(a)(2)(C))
- The person performs the total protein test using a digital refractometer under the supervision of one of the authorized individuals who is physically onsite in the licensed plasma collection center and is available for consultation and direction while the person is processing specimens and performing the test. (BPC § 1246.7(a)(3))
- Authorizes the following individuals to supervise the person:
- A moderate complexity laboratory technical consultant, as specified. (BPC § 1246.7(a)(3)(A))
- A licensed registered nurse. (BPC § 1246.7(a)(3)(B))
- A licensed physician or surgeon. (BPC § 1246.7(a)(3)(C))
- A clinical laboratory director licensed pursuant to this chapter. (BPC § 1246.7(a)(3)(D))
- The person performs the total protein test using a digital refractometer in accordance with (1) standardized operating procedures required by the licensed plasma collection center’s license and (2) standardized procedures developed and approved by the licensed plasma collection center’s supervising physician and surgeon or licensed clinical laboratory director for administration of the total protein test by the persons authorized to perform the total protein test pursuant to this section. These standardized procedures must be made available to the CDPH upon request. (BPC § 1246.7(a)(4))
- The person does not draw the blood sample required for the test using a procedure that requires a registration, certification, or license under state law unless the person is properly registered, certified, or licensed to perform the procedure. (BPC § 1246.7(a)(5))
- The person’s in performing total protein tests using a digital refractometer is evaluated before testing on donors, and again every six months, by the CLIA lab director or technical consultant by direct observation. A licensed plasma collection center must maintain documentation of the competency evaluation, which must be made available to the CDPH upon request. (BPC § 1246.7((a)(6))
- The person accurately records the results of the total protein test in a federal FDA 510k-approved blood establishment computer system (BECS), which must be verified. (BPC § 1246.7(a)(7))
- The person’s results are verified in one of the following ways:
- Using a digital refractometer that creates an electronic record of the test results. (BPC § 1246.7(a)(7)(A))
- Having each record entered by the individual verified for accuracy at the time the test result is recorded and while the result remains visible on the digital refractometer by a registered nurse or by the individual who is supervising the individual performing the test. The individual certifying the accuracy shall affix their name to the record verifying the accuracy of the entries. (BPC § 1246.7(a)(7)(B))
- Affixing a date- and time-stamped photograph of the digital refractometer test results to the spreadsheet. (BPC § 1246.7(a)(7)(C))
- The plasma collection center utilizing a double blind computer entry system that requires the test results to be accurately entered into the record twice before the results are recorded as final. (BPC § 1246.7(a)(7)(D))
- Requires the digital refractometer used to perform a total protein test pursuant under this exemption to meet specified criteria. (BPC § 1246.7(b))
- Specifies following device criteria:
- Is used within 30 feet of the donor for whom the test is being conducted. (BPC § 1246.7(b)(1))
- Is used in accordance with the donor test management system, the quality control program, and the comprehensive quality assurance program established and maintained by the laboratory, as specified. (BPC § 1246.7(b)(2))
- Performs total protein tests classified as waived or of moderate complexity under the federal Clinical Laboratory Improvement Amendments of 1988 (CLIA) (42 U.S.C. Sec. 263a). (BPC § 1246.7(b)(3))
- Performs total protein tests using a digital refractometer on biological specimens that require manual blood collection, centrifugation to separate the blood cells from the plasma, pipetting the plasma from the cells, and application of the plasma into the refractometer. (BPC § 1246.7(b)(4))
- Provides total protein test results without calculation or discretionary intervention by the testing personnel. (BPC § 1246.7(b)(5))
- Performs total protein tests without the necessity for testing personnel to perform calibration or maintenance, except basic cleaning, resetting, and daily standardization pursuant to the manufacturer’s instructions. (BPC § 1246.7(b)(6))
- Requires a licensed plasma collection center to assess the competency and performance of persons authorized to perform the total protein test pursuant to this authorization and to make any required information or test results available to the CDPH, as specified. (BPC § 1246.7(c))
- Requires records of digital refractometer test results collected to be maintained for three years and made available to the CDPH upon request. (BPC § 1246.7(d))
- Specifies that this authorization remains in effect only until January 1, 2021.
FISCAL EFFECT: Unknown. This bill is keyed fiscal by the Legislative Counsel.
COMMENTS:
Purpose. This bill is sponsored by the Plasma Protein Therapeutics Association. According to the author, “By allowing trained and qualified plasma donation centers employees to perform the total protein test with a digital refractometer, [this bill] will make sure four things: 1) licensed individuals are utilized to the highest level of their job skills resulting in more efficient source plasma donor screening; 2) it will ensure appropriate controls are in place for the digital refractometer to maintain continued donor safety when a Total Protein Test is administered; 3) bring California in line with the majority of other states that allow a Total Protein Test to be administered this way and; 4) will ensure Californians with rare disease have appropriate access to the ‘lifesaving drug’ that plasma proteins therapies provide.
Background. This bill would extend an exemption under California clinical laboratory testing requirements by two years, allowing an unlicensed individual to perform a total protein test using a digital refractometer during the donor screening process at plasma donation centers until January 1, 2023. The sponsor of this bill represents private sector manufacturers of plasma protein therapies and collectors of source plasma. According to the sponsor, plasma protein therapies are used to treat medical conditions resulting from insufficient levels of plasma protein, including immune deficiencies and bleeding disorders.
The manufacturers and collectors require plasma donations in order to produce the therapies. In the U.S., plasma donors are paid, and the amount of payment varies by plasma center. These processes are regulated under federal and state biological product and clinical laboratory laws.
Plasma Derived Biologics. Plasma is a component of whole blood and contains blood proteins, which support ordinary bodily functions. Plasma that is separated from blood for the purposes of manufacturing medical products is known as source plasma. Among other things, source plasma can be used to produce therapeutic proteins. Facilities that produce products derived from blood are regulated and licensed under federal and state biologics laws (42 U.S. Code § 262; BPC §§ 1600-1630).
The process for separating source plasma from whole blood is called plasmapheresis. Like dialysis, plasmapheresis is a process during which blood is removed from a donor, the plasma separated from the formed elements, and the remaining blood is returned to the donor. Due to the risks involved, both federal and state biologics laws impose safety precautions for source plasma donations, including various testing, timing, and fatality reporting requirements.
CLIA. In addition to regulation under the biologics laws, plasma collectors and plasma derivative manufacturers must comply with the clinical laboratory testing requirements under CLIA. Federal and state law require that a plasma collection center test a donor’s total protein level, among other things, prior to undergoing plasmapheresis (42 CFR §640.65(b)(1)(i); CCR, tit. 17, § 1025(b)). According to the sponsor, the total protein test helps detect underlying conditions that may cause complications.
At both the federal and state level, a facility that performs laboratory tests on human specimens for diagnostic or assessment purposes must be certified under CLIA. While CLIA establishes the minimum standards under federal law, it allows states to establish more stringent requirements under state law.
In all cases, the requirements for CLIA certification vary depending on the complexity of the laboratory tests performed. Clinical laboratories or other testing sites need to know whether each test system used is waived, moderate, or high complexity. In general, the more complicated the test, the more stringent the requirements, including increased training and licensing of laboratory personnel. At a minimum, all laboratories must have a licensed clinical laboratory director.
The FDA determines the complexity of laboratory tests under CLIA. Waived tests are simple tests with a low risk for an incorrect result. They include tests listed in the CLIA regulations, tests cleared by the FDA for home use, and tests approved for waiver by the FDA using the CLIA criteria. Tests not classified as waived are assigned a moderate or high complexity category based on seven criteria given in the CLIA regulations, including ease of use, knowledge required, and types of materials tested. For commercially available FDA-cleared or approved tests, the test complexity is determined by the FDA during the pre-market approval process.
At the federal level and in California, anyone may perform a waived test in a licensed laboratory. For moderate complexity tests, federal law requires that, at a minimum, personnel have 1) a high school diploma or equivalent and 2) documentation of training appropriate for the testing performed prior to analyzing patient specimens.
However, in California, only specified licensed, certified, or otherwise authorized individuals may perform moderate complexity tests. There are two exceptions allowing unlicensed individuals to perform a moderate complexity test in California. One is for anyone performing a blood gas analysis under BPC § 1245 and anyone in a physician’s office laboratory with a physician readily available.
Total Protein Digital Refractometer Test. According to the sponsors, the centers typically use a digital refractometer to perform the total protein test, which the FDA has categorized as a moderate complexity test. A refractometer is a device that shines a beam of light through a sample of liquid. The device measures the amount of light that is refracted (bent) due to the solids in the sample. In blood, protein causes light to bend. The greater the amount of protein, the more light is bent from the light path.
There are multiple types of protein refractometer devices, ranging from manual to automatic and handheld to benchtop. Depending on the device, the rest requires varying, small samples of blood from the donor, which is then placed into the device. Generally, a manual device requires the user to analyze the sample and calculate the result. An automatic device performs the analysis without input from the user and displays the result, which the user then compares to a set of standard guidelines for total protein levels.
The FDA’s medical device database shows that the FDA has classified all total protein refractometer devices as of moderate complexity under CLIA. Because the test is categorized as moderate complexity at the federal level, state law requires that the test is performed by various licensed personnel under the BPC, such as a registered nurse or clinical laboratory scientist. The sponsor argues that the amount of training and education needed for these personnel is in excess of the amount needed for a total protein test using a digital refractometer in a plasma collection facility.
Plasma Donation Statistics. According to the sponsors, In 2019, there 53.5 million donations in the United States. 1.6 million of those donations were made in California plasma donation centers. 226,000 donations were made in New York, the other state that requires a license for the moderate complexity test performance. More than 51.5 million of those donations were performed using the same type of personnel as allowed in the pilot. The sponsors also report that, as of February 28, 2020, there are 849 plasma donation centers in the United States. 27 are in California. 12 are in New York. 810 centers utilize unlicensed personnel.
Plasma Donation and COVID-19. The sponsors of this bill report that they are developing potential treatments for COVID-19 patients using plasma donated by individuals who have recovered from COVID-19. The goal is to use the antibodies found in the collected manufacture of hyperimmune globulins to treat COVID-19 patients. The convalescent plasma is being collected at licensed plasma donation centers in the United States, including California.
Prior Related Legislation. AB 613 (Nazarian), Chapter 799, Statutes of 2018, established the exemption this bill would extend.
AB 757 (Gomez) of 2015 would have authorized a person, who met specified criteria, to perform a total protein refractometer test using an automatic, button-operated refractometer with a digital readout in a licensed plasma collection facility in this state. This bill was vetoed by Governor Brown, who stated that “Failure to perform and report this test accurately could lead to serious health consequences for the donor. The California Department of Public Health does not believe that the standards outlined in the bill for persons to perform this test ensure the health and safety of plasma donors.”
ARGUMENTS IN SUPPORT:
The Plasma Protein Therapeutics Association writes in support, “In 2018, The California Legislature passed legislation to create a pilot to determine if a properly trained individual may satisfactorily perform a total protein test using a digital refractometer in a licensed plasma collection center. This is the federal standard followed in most of the 44 states where plasma is donated.
The pilot has shown that the properly trained, but unlicensed individual is able to satisfactorily perform the total protein test with no harm to the potential donor. These results are not surprising since properly trained but unlicensed individuals perform the total protein test using a digital refractometer in more than 800 source plasma donation centers in the United States. The test is done to make sure an individual is suitable to donate source plasma on a given day.
[This bill] will ensure that licensed professionals are utilized to the highest level of their job skills resulting in more efficient source plasma donor screening. It will free up specialized staff to perform other essential functions in these source plasma donation centers, such as conducting new donor physical examinations. This is critical because the growing clinical need for plasma medicines means we need more source plasma donations. It takes more than 130 source plasma donations to manufacture the Ig needed annually to treat an individual with primary immune deficiency….
This is where California may make a difference. California currently has 26 source plasma donation centers. This is a result of laws that are not conducive to source plasma donation. For comparison, there are more than 100 source plasma donation centers in Texas, more than 60 in Florida, and more than 40 in Ohio…. Plasma donation centers benefit the communities they are in by providing good jobs to more than 50 employees per center and an economic impact of more than $4 million annually.”
ARGUMENTS IN OPPOSITION:
The California Nurses Association writes in opposition, “By shifting work that should be done by licensed and experienced personnel to unlicensed health care workers, [this bill] deskills this workforce and creates potential health risks. The total protein refractometer test is used prior to a donor undergoing plasmapheresis. Because of the risks involved in this procedure, both federal and state laws require that a donor’s total protein level be tested in order to ensure the donor’s safety and well-being. The total protein refractometer test helps detect underlying conditions that may cause complications. If the test is performed incorrectly, significant harm to donor patients could result…. Moreover, supporters have not demonstrated that there is a shortage of licensed and experienced personnel requiring this change in law. [This bill] is simply unnecessary. In addition, it is clear that manufacturers of digital refractometers and other businesses stand to gain financially by this bill. Donor patients, on the other hand, will lose.”
POLICY ISSUE(S) FOR CONSIDERATION:
Sunset Extension. This bill would extend the sunset date on a pilot program put into place in 2018. The goal of the program was to explore the safety of the use of unlicensed personnel or other individuals who are otherwise untrained to generally perform CLIA tests of moderate complexity using an automated digital refractometer to screen potential and repeat plasma donors. The prior bill that established the pilot put numerous patient safety provisions in place, including limiting the device to a class of point of care devices normally used by unlicensed personnel.
The initial version of this bill would have extended the program indefinitely. However, the prior bill provided several mechanisms allowing for the reporting of safety and accuracy data to the CDPH. According to the CDPH, that data is still under review. To allow the CDPH additional time, the author recently accepted amendments that further extended the sunset date.
However, plasma donation centers may not be willing to invest if the program is always at risk of sunsetting, the author may wish to continue to work with the CDPH and stakeholders to determine whether the sunset date should be eliminated upon the CDPH’s review of the data.
IMPLEMENTATION ISSUES:
Training. According to the sponsors, the 5-hour training requirement put in place by the prior bill is arbitrary and redundant, as existing law already requires the plasma donation center and supervisors to appropriately train all personnel. The author recently accepted amendments to reinsert this requirement to allow CDPH additional time to review data. Once the CDPH is able to review the data, the author may wish to continue to work with the CDPH and stakeholders to determine whether the training requirement should be removed or replaced.
Verification. The prior bill required that the unlicensed person accurately record the results of the total protein test in a federal FDA 510k-approved blood establishment computer system. It also required that the unlicensed person verify the results in one of four ways:
- Using a digital refractometer that creates an electronic record of the test results.
- Having each record entered by the individual verified for accuracy at the time the test result is recorded and while the result remains visible on the digital refractometer by a registered nurse or by the individual who is supervising the individual performing the test. The individual certifying the accuracy must affix their name to the record verifying the accuracy of the entries.
- Affixing a date- and time-stamped photograph of the digital refractometer test results to the spreadsheet.
- Using a double blind computer entry system that requires the test results to be accurately entered into the record twice before the results are recorded as final.
According to the sponsors, the verification requirement is onerous and conflicts with federal Good Manufacturing Practices for pharmaceuticals.
The author recently accepted amendments to reinsert this requirement to allow CDPH additional time to review data. Once the CDPH is able to review the data, the author may wish to continue to work with the CDPH and stakeholders to determine whether the verification requirement should be removed or replaced.
Clinical Laboratory Scientist Supervisor. The author recently accepted amendments to add clinical laboratory scientists as a supervisor under this bill at the request of the opposition. That request has been withdrawn. If this bill passes this committee, the author may wish to delete that provision.
REGISTERED SUPPORT:
Plasma Protein Therapeutics Association (sponsor)
American Plasma Users Coalition
Biocom
CSL Behring
Grifols, Inc.
Immune Deficiency Foundation
Takeda Pharmaceuticals America
Over 70 Individuals with Primary Immunodeficiencies
REGISTERED OPPOSITION:
California Nurses Association
Analysis Prepared by: Vincent Chee / B. & P. / (916) 319-3301
Bill Author
Bill Co-Author(s):